INDEMNIFICATION AGREEMENTIndemnification Agreement • February 14th, 2020 • IMARA Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [ ] between IMARA Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • February 14th, 2020 • IMARA Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of [ ], 20[ ] by and between IMARA Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”) [[Solely with respect to officers and directors that execute this form of indemnification agreement on or prior to the Company’s initial public offering:] and shall be effective as of the effectiveness of a Registration Statement on Form S-1 relating to the initial registration under the Securities Act of 1933, as amended, of shares of the Company’s common stock].
IMARA Inc. NONSTATUTORY STOCK OPTION AGREEMENT GRANTED UNDER 2016 STOCK INCENTIVE PLANNonstatutory Stock Option Agreement • February 14th, 2020 • IMARA Inc. • Pharmaceutical preparations
IMARA Inc. STOCK OPTION AGREEMENTStock Option Agreement • February 14th, 2020 • IMARA Inc. • Pharmaceutical preparations
This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • February 14th, 2020 • IMARA Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 15th day of March, 2019 by and among IMARA Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and any additional purchasers that becomes a party to this Agreement in accordance with Section 6.9 hereof, and for purposes of Sections 1, 3.1, 3.2, 3.4(b), 3.6 and 4, H. Lundbeck A/S (“Lundbeck”).
OFFICE LEASE AGREEMENT BY AND BETWEEN COLUMBIA REIT — 116 HUNTINGTON, LLC a Delaware limited liability company AND IMARA INC. a Delaware corporation 116 Huntington Avenue Boston, Massachusetts 02116Office Lease Agreement • February 14th, 2020 • IMARA Inc. • Pharmaceutical preparations • Massachusetts
THIS OFFICE LEASE AGREEMENT (this “Lease”) is dated as of May 20, 2019 (the “Execution Date”), by and between COLUMBIA REIT — 116 HUNTINGTON, LLC, a Delaware limited liability company (“Landlord”), and IMARA INC., a Delaware corporation (“Tenant”).
Imara, Inc. 116 Huntington Ave, 6th Floor Boston, MA 02116 Info@Imaratx.com +1 617 206-2020 www.imaratx.comIMARA Inc. • February 14th, 2020 • Pharmaceutical preparations • Massachusetts
On behalf of IMARA Inc., a Delaware corporation (the “Company”), I am very pleased to offer you this revised “letter agreement” with the Company. This letter agreement shall supersede, amend and restate in all respects the letter agreement between you and the Company dated March 1, 2019, as amended and restated by the letter agreement between you and the Company dated June 27, 2019 (as amended and restated, the “Former Letter Agreement”), provided, and for the avoidance of doubt, that nothing herein supersedes the Employee Confidentiality, Assignment and Noncompetition Agreement signed by you on March 5, 2019 (the “Restrictive Covenants Agreement”), which remains in effect, unaltered, in all respects.
IMARA INC. INCENTIVE STOCK OPTION AGREEMENT GRANTED UNDER 2016 STOCK INCENTIVE PLANIncentive Stock Option Agreement • February 14th, 2020 • IMARA Inc. • Pharmaceutical preparations
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • February 14th, 2020 • IMARA Inc. • Pharmaceutical preparations • New York
This Exclusive License Agreement (this “Agreement”) is made and is effective this 11th day of April, 2016 (the “Effective Date”) between IMARA, INC., a Delaware, U.S.A. corporation (“Licensee”) and having an address at 700 Technology Square, 3rd Floor, Cambridge, MA 02139, and H. LUNDBECK A/S, a for profit corporation organized and existing under the laws of Denmark with company registration no. (CVR) 56759913 (“Licensor”) and having an address at Ottiliavej 9, DK-2500 Valby, Copenhagen, Denmark. Licensee and Licensor are each referred to as a “Party” and collectively referred to as the “Parties.”
Imara, Inc. Boston, MA 02116 Info@Imaratx.comLetter Agreement • February 14th, 2020 • IMARA Inc. • Pharmaceutical preparations • Massachusetts
On behalf of IMARA Inc., a Delaware corporation (the “Company”), I am very pleased to offer you this revised “letter agreement” with the Company. This letter agreement shall supersede, amend and restate in all respects the letter agreement between you and the Company dated April 17, 2018, as amended and restated by the letter agreement between you and the Company dated August 12, 2019 (as amended and restated, the “Former Letter Agreement”), provided, and for the avoidance of doubt, that nothing herein supersedes the Invention and Non-Disclosure Agreement or the Non-Competition and Non-Solicitation Agreement signed by you concurrently with the Former Letter Agreement (the “Restrictive Covenant Agreements”), which remain in effect, unaltered, in all respects.
IMARA Inc. RESTRICTED STOCK UNIT AGREEMENTRestricted Stock Unit Agreement • February 14th, 2020 • IMARA Inc. • Pharmaceutical preparations
This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
